Clincosm LogoSign in Get a demo

Epidemiological Features and Clinical Course of COVID -19 Infection in Cancer Patients: The Rovid Study

Sponsor
Istituto Oncologico Veneto IRCCS (Other)
Overall Status
Recruiting
CT.gov ID
NCT04811781
Collaborator
(none)
300
Enrollment
3
Locations
23.9
Anticipated Duration (Months)
100
Patients Per Site
4.2
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The study aims to retrospectively collect epidemiological and clinical data in patients with solid tumors and SARS Covid2 infections belonging to oncology centers within the Veneto Oncology Network

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    The aim of this study is to create a Veneto Oncology Network with the aim of collecting clinical and epidemiological data of cancer Patients affected by SAR- Covid-2 infection over a period of 1 year. Descriptive statistical approaches will be used to process the data.

    The aim is to evaluate the development rate of severe clinical forms of infection in patients with SARS-Cov-2 and the possible association with tumour characteristics and treatment.

    In addition, the results of serological tests can be compared with the outcome of the diagnostic swabs and the clinical evolution of the infection in order to obtain more information regarding the significance of specific antibody development.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    300 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Epidemiological Features and Clinical Course of SARS-CoV-2 Infection in Cancer Patients Within the Veneto Oncology Network: the ROVID Study
    Actual Study Start Date :
    Jun 4, 2020
    Actual Primary Completion Date :
    Jun 4, 2021
    Anticipated Study Completion Date :
    Jun 1, 2022

    Arms and Interventions

    Arm Intervention/Treatment
    Cancer Patients with SARS-COV-2 infection.

    Outcome Measures

    Primary Outcome Measures

    1. The rate of SAR-COV2 infection development in association with tumor characteristics. [through study completion, an average of 18 months.]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 65 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    • be 18 Years and older

    • cancer patients belonging to Veneto 's Oncological Network

    • Patients with SAR COV-2 infection

    Exclusion Criteria:

    • Patients with no SAR COV2 Infection

    • Volunteers

    • No Cancer Patients

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 istituto Oncologico Veneto -UOSD Melanoma Padova PD Italy
    2 Aulss1 Dolomiti Belluno Italy
    3 Istituto Oncologico Veneto -UOC Oncologia 1 Padova Italy

    Sponsors and Collaborators

    • Istituto Oncologico Veneto IRCCS

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Istituto Oncologico Veneto IRCCS
    ClinicalTrials.gov Identifier:
    NCT04811781
    Other Study ID Numbers:
    • Rovid
    First Posted:
    Mar 23, 2021
    Last Update Posted:
    Apr 1, 2022
    Last Verified:
    Mar 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Infections

    Study Results

    No Results Posted as of Apr 1, 2022